L-274-2023

Agreement ID
L-274-2023
Lead IC
NIAID
Exclusivity
Nonexclusive
External Party
ModernaTX, Inc.
Fiscal Year
2025
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-2717     Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
TAB-3336     Substitutions-Modified Prefusion RSV F Proteins and Their Use